Various major drug manufacturers are increasingly gaining regulatory drug approval for the treatment of kidney cell carcinoma. These major players are bringing in new and excellent drug candidates to gain more market share. For the treatment of kidney cell carcinoma the increasing production of innovative drugs will lead to market growth in the estimated period.
For example, the US Food and Drug Administration (FDA) approved Bristol-Myers Squibb Company’s Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg injection in April 2018, for arterial use, as the first immuno-oncology composition therapy with previously untreated patients central and malignant-advanced kidney cell carcinoma. The composition reduced the risk of death by 37% compared to Sutent: a kinase inhibitor specified for the treatment of new kidney cell carcinoma and supplementary treatment of adult patients at high risk of chronic kidney cell carcinoma after nephrectomy.
Get Free PDF Sample Copy of this report @
In 2016, the FDA approved Cabometyx for the treatment of patients with advanced kidney cell carcinoma who had previously received anti-angiogenic therapy. U.S. The FDA has approved Exelixis, Inc. in December 2017, Cabozantinib (Cabometyx) is routinely recognized as the first-class treatment for patients with new kidney cell carcinoma.
Moreover, key players are focusing on product development through strategic collaboration and business expansion in emerging markets. This can make the market more competitive, increase the revenue of key players and offer a profitable growth outlook over the approximate period. Biosimilar development is gaining traction as a promising market opportunity in the treatment of kidney cancer. A number of biotech companies have introduced Avastin Biosimilars on emerging cancer signals in emerging markets such as Argentina, Russia and India.
For example, Biocon Ltd. introduced bevacizumab in November 2017, 100 mg/4 ml vials and 400 mg/16 ml vials formulations under the brand name Krabeva in India for the treatment of many types of cancer. Krabeva is indicated as a first class treatment for patients with metastatic colorectal cancer and is used to treat cancers of the brain, ovaries, cervix, kidneys, and lungs.
Covid-19 Impact Analysis
Globally, as of December 29, 2021, there have been 281,808,270 confirmed cases of COVID-19, including 5,411,759 deaths, reported to WHO. As of January 2, 2022, a total of 8,693,832,171 vaccine doses have been administered.
Request PDF Brochure with Latest Insights @
Of the therapeutic classes, the targeted therapy segment had a large market share in 2017. Researchers in the field of oncology are focusing on kidney cancer cells and developing new drugs targeting molecular and genetic mutations. Targeted drugs differ from standard chemotherapy drugs and offer satisfactory results in the treatment of kidney cancer, where chemotherapy has not been shown to be very effective.
Of the pharmacological classes, the angiogenesis inhibitor segment had the largest share in 2017. Angiogenesis inhibitor drugs play an important role in inhibiting the growth of cancer cells. Angiogenesis inhibitors block the supply of nutrients and oxygen to the tumor in the kidney. Some angiogenesis inhibitor drugs used in the treatment of kidney cancer include Axitinib (inlyta), bevacizumab (Avastin), and cabozantinib (cometriq).
Of the distribution channels, the hospital pharmacy department has the largest share in 2017. Hospital pharmacies serve as the primary distribution channel for cancer-specific drugs and treatments. Patients undergoing treatment for cancer in hospital facilities rely heavily on hospital-affiliated pharmacies for prescribing medications and tracking drug history.
Key players working in the global kidney cancer drugs market are, Eisai Co., Ltd., Cipla Ltd., Exelixis Inc., Amgen Inc., Genentech, Inc., Pfizer Inc., Bayer AG, Hoffmann-La Roche AG, Novartis International AG, Bristol-Myers Squibb Company, and Active Biotech AB.
Reasons to Buy this Kidney Cancer Drugs Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Kidney Cancer Drugs market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Kidney Cancer Drugs market
➡Leading company profiles reveal details of key Kidney Cancer Drugs market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Kidney Cancer Drugs market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Kidney Cancer Drugs Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Kidney Cancer Drugs Industry Impact
Chapter 2 Global Kidney Cancer Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Kidney Cancer Drugs (Volume and Value) by Type
2.3 Global Kidney Cancer Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Kidney Cancer Drugs Sales, Consumption, Export, Import by Regions
Chapter 5 North America Kidney Cancer Drugs Market Analysis
Chapter 6 East Asia Kidney Cancer Drugs Market Analysis
Chapter 7 Europe Kidney Cancer Drugs Market Analysis
Chapter 8 South Asia Kidney Cancer Drugs Market Analysis
Chapter 9 Southeast Asia Kidney Cancer Drugs Market Analysis
Chapter 10 Middle East Kidney Cancer Drugs Market Analysis
Chapter 11 Africa Kidney Cancer Drugs Market Analysis
Chapter 12 Oceania Kidney Cancer Drugs Market Analysis
Chapter 13 South America Kidney Cancer Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Kidney Cancer Drugs Business
Chapter 15 Global Kidney Cancer Drugs Market Forecast (2021-2028)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027